Key Points
- David Badawi, Sight Sciences' CTO, sold 4,836 shares on Jan. 16 at $6.62 for $32,014, leaving him with 1,912,273 shares (a 0.25% stake reduction); he also sold 3,695 (Jan. 6), 3,051 (Jan. 5) and 2,914 (Jan. 2), totaling 14,496 shares sold across Jan. 2–16 for roughly $105,163.
- Sight Sciences trades near $6.38 with a 50-day SMA of $7.78 and a 52-week range of $2.03–$9.24, is currently unprofitable (negative EPS/PE) with a market cap of about $337M, and carries a consensus analyst "Hold" rating with an average target of $8.30.
Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CFO James Rodberg sold 2,616 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $6.62, for a total transaction of $17,317.92. Following the transaction, the chief financial officer directly owned 151,230 shares of the company's stock, valued at $1,001,142.60. This represents a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
James Rodberg also recently made the following trade(s):
- On Tuesday, January 6th, James Rodberg sold 594 shares of Sight Sciences stock. The stock was sold at an average price of $7.48, for a total transaction of $4,443.12.
- On Monday, January 5th, James Rodberg sold 4,405 shares of Sight Sciences stock. The shares were sold at an average price of $7.82, for a total transaction of $34,447.10.
Sight Sciences Stock Performance
Shares of SGHT opened at $6.38 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.93 and a current ratio of 9.60. Sight Sciences, Inc. has a 52-week low of $2.03 and a 52-week high of $9.24. The stock has a market capitalization of $337.31 million, a price-to-earnings ratio of -7.09 and a beta of 2.42. The stock's 50-day simple moving average is $7.78 and its 200 day simple moving average is $5.33.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.10. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. The business had revenue of $19.91 million during the quarter, compared to analyst estimates of $17.74 million. Research analysts forecast that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.
Wall Street Analyst Weigh In
SGHT has been the topic of a number of research analyst reports. Morgan Stanley increased their price objective on shares of Sight Sciences from $6.00 to $8.00 and gave the company an "equal weight" rating in a research report on Tuesday, December 2nd. Weiss Ratings reiterated a "sell (e+)" rating on shares of Sight Sciences in a research note on Monday, December 29th. Citigroup raised their price target on Sight Sciences from $5.50 to $9.10 and gave the stock a "neutral" rating in a research note on Thursday, December 11th. Raymond James Financial set a $9.00 price objective on Sight Sciences in a report on Monday, January 5th. Finally, Piper Sandler set a $9.00 target price on Sight Sciences in a research report on Monday, January 5th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Sight Sciences currently has a consensus rating of "Hold" and an average target price of $8.30.
Get Our Latest Analysis on Sight Sciences
Hedge Funds Weigh In On Sight Sciences
Institutional investors have recently bought and sold shares of the stock. Americana Partners LLC bought a new position in shares of Sight Sciences during the 2nd quarter valued at approximately $3,568,000. Vanguard Group Inc. increased its stake in Sight Sciences by 5.7% in the third quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company's stock worth $6,559,000 after purchasing an additional 102,609 shares during the period. B Group Inc. increased its position in Sight Sciences by 11.6% during the 2nd quarter. B Group Inc. now owns 930,000 shares of the company's stock valued at $3,841,000 after purchasing an additional 96,400 shares during the period. Palumbo Wealth Management LLC bought a new position in Sight Sciences in the second quarter worth about $328,000. Finally, Millennium Management LLC raised its position in shares of Sight Sciences by 145.2% in the 3rd quarter. Millennium Management LLC now owns 133,846 shares of the company's stock valued at $460,000 after purchasing an additional 79,265 shares during the last quarter. 55.51% of the stock is owned by hedge funds and other institutional investors.
About Sight Sciences
(
Get Free Report)
Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.
Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
